Abstract:
OBJECTIVE:The study investigated the efficacy and tolerability of teneligliptin co-administered to patients with type 2 diabetes mellitus (T2DM) who were inadequately controlled by stable metformin monotherapy ≥ 1000 mg/day. METHODS:A total of 447 patients from 55 European centers who completed a 14-day screening and 14-day run-in phase, received randomized double-blind treatment with 5, 10, 20 or 40 mg teneligliptin or placebo once daily, for 24 weeks. 364 patients continued treatment in a 28-week open label extension during which they received teneligliptin 20 mg once daily. RESULTS:Co-administration of teneligliptin (5 to 40 mg) with metformin demonstrated dose-related and statistically significant reductions in HbA1c after 24 weeks (-0.30 to -0.63% placebo adjusted) of double-blind treatment. The greatest reduction in HbA1c was seen with teneligliptin at 40 mg (-0.63%) at Week 24. There was also a dose-dependent increase in proportion of responders achieving HbA1c < 7.0% at this endpoint. Responses were maintained throughout 28 weeks open label treatment with 20 mg teneligliptin. Treatment was well tolerated to Week 52 and the overall incidence of hypoglycemia during 52 weeks was 2.3%. CONCLUSIONS:Teneligliptin co-administered with metformin produced significant reductions in HbA1c in patients with T2DM without increasing the risk of hypoglycemia.
journal_name
Expert Opin Pharmacotherjournal_title
Expert opinion on pharmacotherapyauthors
Bryson A,Jennings PE,Deak L,Paveliu FS,Lawson Mdoi
10.1080/14656566.2016.1190334subject
Has Abstractpub_date
2016-07-01 00:00:00pages
1309-16issue
10eissn
1465-6566issn
1744-7666journal_volume
17pub_type
杂志文章,随机对照试验abstract:OBJECTIVE:To explore the treatment response, tolerability and safety of once-monthly paliperidone palmitate (PP1M) in non-acute patients switched from oral antipsychotics, stratified by time since diagnosis as recently diagnosed (≤3 years) or chronic patients (>3 years). RESEARCH DESIGN AND METHODS:Post hoc analysis o...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,多中心研究
doi:10.1080/14656566.2016.1174692
更新日期:2016-06-01 00:00:00
abstract::Although effective anti-neoplastic agents, anthracyclines are limited by their well recognized and pervasive cardiotoxic effects. The incidence of late progressive cardiovascular disease in long-term survivors of cancer is established and may contribute to heart failure and death. To maximize the benefits of these dru...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.8.8.1039
更新日期:2007-06-01 00:00:00
abstract::The 1st International Conference on Psychophysiology of Panic Attacks focused on the diversity of treatments and theories in this complex condition. Experimental research topics were featured, as well as treatment strategies, case studies and patient perspectives. The conference aimed to create a strong multi-cultural...
journal_title:Expert opinion on pharmacotherapy
pub_type:
doi:10.1517/14656566.5.4.977
更新日期:2004-04-01 00:00:00
abstract:BACKGROUND:Tamoxifen is the established adjuvant treatment for postmenopausal women with hormone-sensitive breast cancer. OBJECTIVE:To determine whether the aromatase inhibitor anastrozole should replace tamoxifen as the adjuvant treatment in this cancer. METHODS:Two recent trials of anastrozole and tamoxifen as adju...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1517/14656566.9.9.1619
更新日期:2008-06-01 00:00:00
abstract::Hyperlipidaemia is a pivotal risk factor for the development of atherosclerotic disease. A large number of studies have demonstrated that the treatment of abnormalities in lipoprotein levels reduces the risk for myocardial infarction, peripheral vascular disease, carotid artery disease, stroke, and cardiovascular mort...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.6.1.131
更新日期:2005-01-01 00:00:00
abstract:INTRODUCTION:Hairy cell leukemia (HCL) is a B-cell lymphoid malignancy that accounts for approximately 2% of all leukemias. Treatment with purine nucleoside analogs (PNA) results in a high response rate and remains the standard of care. Long term follow-up shows that most patients relapse and require retreatment. Newer...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2020.1754397
更新日期:2020-08-01 00:00:00
abstract::Pain may produce metabolic changes after surgery, which may contribute to further morbidity. A variety of medicines and techniques can be used to successfully treat pain. It is postulated that improved analgesia leads to improved outcomes, although analgesics may also contribute to morbidity. This article reviews the ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.4.9.1507
更新日期:2003-09-01 00:00:00
abstract::Candesartan is a long-acting angiotensin receptor antagonist that is well absorbed from the gastrointestinal tract, with insurmountable receptor binding abilities. Recent studies have shown candesartan to be an effective therapy for heart failure patients, producing a significant reduction in mortality and morbidity. ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.7.14.1945
更新日期:2006-10-01 00:00:00
abstract::There is accumulating evidence that tumour necrosis factor (TNF) plays a major role in the pathogenesis of rheumatoid arthritis (RA). Recent biotechnological advances have allowed for the development of agents that directly target TNF, a pro-inflammatory cytokine. In the last 2 years, the US FDA and the EU's Commissio...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2.1.75
更新日期:2001-01-01 00:00:00
abstract::Introduction: Triptorelin is a luteinizing hormone-releasing hormone analog (LH-RHa) inducing ovarian function suppression (OFS). It is approved by FDA and EMA in association with tamoxifen or aromatase inhibitor (AI) and with fulvestrant and palbociclib in premenopausal women with hormone receptor (HR)-positive breas...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1080/14656566.2019.1650020
更新日期:2019-10-01 00:00:00
abstract::The long-term beta-blockade strategy with carvedilol, metoprolol succinate or bisoprolol is now strongly recommended to reduce the rates of mortality and morbidity in patients with chronic heart failure (CHF). Although the benefits observed with such drugs are viewed as a class effect, theoretically, carvedilol might ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1517/14656566.5.6.1359
更新日期:2004-06-01 00:00:00
abstract::Anticoagulants are used for the prevention and treatment of venous thromboembolism and for the secondary prevention of stroke and myocardial infarction. The list of available anticoagulants includes unfractionated heparin, low molecular weight heparins, fondaparinux, warfarin and the direct thrombin inhibitors. Numero...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.7.8.989
更新日期:2006-06-01 00:00:00
abstract::Neonatal herpes is a potentially devastating consequence of perinatal transmission of the herpes simplex virus (HSV), with significant morbidity and mortality. Treatment options are available, but must begin early in disease with manifestations that are often protean. Thus, preventive measures need to be optimised. An...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.4.10.1809
更新日期:2003-10-01 00:00:00
abstract:INTRODUCTION:Cardiovascular disease is a major cause of death, and hypercholesterolemia is a major risk factor. Statins, with simvastatin among the most widely used, have ample evidence demonstrating prevention of cardiovascular events and mortality. Ezetimibe is effective at improving serum lipids in combination with ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2015.1041504
更新日期:2015-06-01 00:00:00
abstract:INTRODUCTION:Asthma is the most common chronic disease in childhood, affecting approximately 10% of all children, and is the leading cause of hospitalization in developed countries. In this paper we aimed to review the evidence on chemical pharmacotherapy for long-term treatment of pediatric asthma, according to the la...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2017.1317747
更新日期:2017-05-01 00:00:00
abstract::Almotriptan is a serotonin (5-hydroxytryptamine, 5HT)(1B/1D)-receptor agonist approved for the acute treatment of migraine. In 3500 acute migraine patients enrolled in short-term trials and 1500 patients in long-term open-label trials, almotriptan 12.5 mg was effective and well-tolerated. Almotriptan maintains a consi...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.4.7.1157
更新日期:2003-07-01 00:00:00
abstract:INTRODUCTION:Treatment options for hair disorders are generally very limited. These options are even more limited in children due to the lack of trials and clinical research. Moreover, physicians are sometimes scared to treat children with drugs without safety data, especially because most hair disorders are benign. A...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2016.1217990
更新日期:2016-09-01 00:00:00
abstract:INTRODUCTION:Flecainide is a class Ic antiarrhythmic agent available in Europe since 1982. The clinical development program of flecainide provided good data on its antiarrhythmic effect for the prevention of ventricular and supraventricular arrhythmias. The Cardiac Arrhythmia Suppression Trial (CAST), conducted to test...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2013.759212
更新日期:2013-02-01 00:00:00
abstract::This is a review of the literature comparing the efficacy and safety of drug-eluting stents (DES) versus bare-metal stents (BMS) in patients with acute myocardial infarction (MI). The present article reviews whether DES are beneficial in the setting of primary percutaneous coronary intervention (PCI), and this has bee...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656560802627952
更新日期:2009-01-01 00:00:00
abstract::Asthma is a chronic disease of the airways in which inflammation causes bronchial hyper-reactivity and attacks of wheezing, dyspnea and chest tightness that are triggered by various agents. It requires both acute treatment of the paroxistical respiratory symptoms with reliever medications and maintenance treatment, wh...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1517/14656566.7.9.1235
更新日期:2006-06-01 00:00:00
abstract:INTRODUCTION:Only 40-60% of obsessive-compulsive patients respond to first line treatments, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy. Several second-line treatments have been investigated in the last two decades, and most of them seem to work, at least in a subset of pati...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1080/14656566.2018.1528230
更新日期:2018-10-01 00:00:00
abstract:INTRODUCTION:Psoriasis is a chronic, inflammatory disease afflicting 2% of the US population; it results in significant morbidity. The annual healthcare costs related to psoriasis are an estimated $11.3 billion and, with an expanding biologic market, an updated costs analysis is needed. AREAS COVERED:Current treatment...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2011.590475
更新日期:2011-09-01 00:00:00
abstract:INTRODUCTION:The bcr-abl tyrosine kinase inhibitors (TKIs) are the cornerstone treatment for chronic myeloid leukemia (CML). However, there are many topics related to therapy that remain debated. AREAS COVERED:The aim of this paper is to give the reader a comprehensive review of how to treat CML at diagnosis, how to m...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2012.671296
更新日期:2012-04-01 00:00:00
abstract::In recent years, hepatitis C virus-related arthritis (HCVrA) has been recognised as an autonomous rheumatic disorder. Two subsets of the disease have been identified: a polyarthritis involving small joints that resembles rheumatoid arthritis, but is usually milder, and a mono-oligoarthritis that shows an intermittent ...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.6.1.27
更新日期:2005-01-01 00:00:00
abstract:OBJECTIVE:To compare the efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring (CGM) in a single-day treatment setting. METHODS:This was a post hoc analysis of a randomized crossover study comparing the efficacy of...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,随机对照试验
doi:10.1517/14656566.2015.1035646
更新日期:2015-06-01 00:00:00
abstract:INTRODUCTION:Docetaxel and paclitaxel are among the most active agents for the treatment of breast cancer. These first-generation taxanes are extremely hydrophobic; therefore, solvents are needed for its parenteral administration. Albumin nanoparticle technology allows for the transportation of such hydrophobic drugs w...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.2012.651127
更新日期:2012-02-01 00:00:00
abstract:BACKGROUND:In the first decade of the 21st century, worm infections are still very common, especially--but not exclusively--in the developing world. OBJECTIVE:To review the current pharmacotherapy of the major trematode, cestode and nematode infections of humans. METHODS:A systematic search of the Cochrane Databank o...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656560902722463
更新日期:2009-02-01 00:00:00
abstract:INTRODUCTION:Chronic spontaneous urticaria (CSU) refers to urticaria (wheals) or angioedema, which occur for a period of six weeks or longer without an apparent cause. The condition may impair the patient's quality of life. AREAS COVERED:Treatment for CSU is mainly symptomatic. Both AAAAI/ACAAI practice parameters and...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章
doi:10.1080/14656566.2020.1829593
更新日期:2020-09-29 00:00:00
abstract::Efavirenz is a non-nucleoside reverse transcriptase inhibitor that in most treatment guidelines is recommended to be taken combined with two nucleoside analogue reverse transcriptase inhibitors, as a preferred first-line regimen for the treatment of HIV-1 infection. The antiretroviral efficacy of efavirenz-based combi...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.8.6.851
更新日期:2007-04-01 00:00:00
abstract::The orofacial complications of HIV infection are diverse, include opportunistic infection and malignancy and in many instances are region specific. Although effective management strategies to treat HIV-associated oral disease have been developed in North America and Europe, the evidence base on which these rely remain...
journal_title:Expert opinion on pharmacotherapy
pub_type: 杂志文章,评审
doi:10.1517/14656566.9.3.387
更新日期:2008-02-01 00:00:00